Treatment of HER2+ Breast Cancer: Insights from Experts at Texas Oncology, UT Southwestern Dallas, and UT Health San Antonio - Episode 1

Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)

, , ,

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Now Viewing
EP. 1: Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)
EP. 2: Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC
EP. 3: Screening for Brain Metastases in HER2+ Breast Cancer
EP. 4: Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan
EP. 5: Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain Metastases
EP. 6: Treatment Approaches in HER2+ mBC with Brain Metastases
EP. 7: Managing Adverse Events of Tucatinib in Patients with HER2+ mBC with Brain Metastases
EP. 8: Leptomeningeal Metastases in HER2+ mBC
EP. 9: Systemic Therapy Before Whole Brain Radiation for HER2+ mBC with Brain Metastases
EP. 10: Case Presentation: A 62-Year-Old Woman with HER2+ mBC with Pulmonary and Brain Metastases
EP. 11: Future Perspectives in HER2+ mBC

Related Content:

Treatment of HER2+ Breast Cancer: Insights from Experts at Texas Oncology, UT Southwestern Dallas, and UT Health San AntonioBreast CancerHER2-Positive Breast CancerAround the Practice
Kevin Kalinsky, MD, MS, Discusses the Past, Present, and Future of Breast Cancer Research
Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer Experience
Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors